Want to see QNCX full AI Analyst Report?
Top Page
Quince Therapeutics
(NASDAQ:QNCX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$31.00
▲(0.23% Upside)
Action:Reiterated
Date:09/06/26
Overall score is weighed down primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn) and added downside risk from Nasdaq listing compliance challenges. Technicals provide a partial offset with moderately positive trend/momentum, but valuation signals remain weak due to losses and no dividend support.
Positive Factors
No debt and positive TTM equity
The current absence of debt reduces interest and refinancing pressure, while positive TTM equity provides a stronger capital base for advancing clinical programs. This financial flexibility is valuable for a development-stage biotech, although continued losses could change the position.
Negative Factors
No commercial revenue and widening losses
Quince has no marketed-product revenue to offset its research and operating costs, while losses are increasing as development spending continues. This leaves future financial performance dependent on clinical progress, financing, partnerships, or eventual product approval.
Read all positive and negative factors
Positive Factors
Negative Factors
No debt and positive TTM equity
The current absence of debt reduces interest and refinancing pressure, while positive TTM equity provides a stronger capital base for advancing clinical programs. This financial flexibility is valuable for a development-stage biotech, although continued losses could change the position.
Read all positive factors
Quince Therapeutics (QNCX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$31.85M
Dividend YieldN/A
Average Volume (3M)30.11K
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue GrowthN/A
EPS Growth43.02%
CountryUS
Employees38
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-68.91
Shares Outstanding1,017,063
10 Day Avg. Volume19,547
30 Day Avg. Volume30,105
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-4.70
Price to Sales (P/S)0.00
P/FCF Ratio-4.02
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$79.60Price Target Upside157.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-8.3
Revenue Forecast (FY)N/A
Quince Therapeutics Business Overview & Revenue Model
Company Description
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineer...
How the Company Makes Money
As a clinical-stage biotechnology company, Quince Therapeutics does not have a stable, recurring product-revenue base from commercial drug sales (null for material marketed-product revenue streams). Its funding and cash inflows have historically b...
Quince Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
41
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -36.00K | -142.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -72.33M | -80.62M | -35.98M | -26.82M | -50.99M | -89.60M |
| Net Income | -92.48M | -83.98M | -56.83M | -31.39M | -51.66M | -89.94M |
Balance Sheet | ||||||
| Total Assets | 124.00M | 93.52M | 114.48M | 180.20M | 103.91M | 133.23M |
| Cash, Cash Equivalents and Short-Term Investments | 115.98M | 17.75M | 40.78M | 75.06M | 90.18M | 106.80M |
| Total Debt | 0.00 | 18.47M | 14.81M | 13.81M | 453.00K | 1.16M |
| Total Liabilities | 15.51M | 129.24M | 84.33M | 95.12M | 3.32M | 14.64M |
| Stockholders Equity | 108.49M | -35.71M | 30.15M | 85.08M | 100.59M | 118.59M |
Cash Flow | ||||||
| Free Cash Flow | -47.00M | -41.78M | -32.16M | -18.45M | -44.17M | -63.11M |
| Operating Cash Flow | -46.92M | -41.42M | -31.90M | -18.29M | -44.04M | -62.93M |
| Investing Cash Flow | 26.29M | 23.23M | 21.91M | -5.76M | 18.00M | 58.95M |
| Financing Cash Flow | 121.79M | 17.91M | -4.78M | 143.00K | 707.00K | 6.81M |
Quince Therapeutics Technical Analysis
Negative
30.93
Price Trends
25.14
Positive
23.95
Positive
175.49
Negative
Market Momentum
1.65
Positive
54.62
Neutral
25.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNCX, the sentiment is Negative. The current price of 30.93 is below the 20-day moving average (MA) of 32.47, above the 50-day MA of 25.14, and below the 200-day MA of 175.49, indicating a neutral trend. The MACD of 1.65 indicates Positive momentum. The RSI at 54.62 is Neutral, neither overbought nor oversold. The STOCH value of 25.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QNCX.
Quince Therapeutics Risk Analysis
Quince Therapeutics disclosed 83 risk factors in its most recent earnings report. Quince Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quince Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $240.37M | -7.59 | -29.09% | ― | 8906.15% | 41.48% | |
47 Neutral | $71.83M | -0.78 | -53.22% | ― | ― | 55.84% | |
45 Neutral | $31.85M | -0.45 | -413.28% | ― | ― | 43.02% | |
44 Neutral | $209.14M | -1.86 | -39.64% | ― | ― | -6.70% | |
33 Underperform | $14.63M | -1.85 | -74.58% | ― | ― | 33.15% |
* Healthcare Sector Average
QNCX
Quince Therapeutics
29.50
-292.50
-90.84%
PLRX
Pliant Therapeutics
1.14
-0.62
-35.14%
NKTX
Nkarta
3.23
1.16
56.04%
ADAG
Adagene
3.49
0.99
39.60%
ANEB
Anebulo Pharmaceuticals
0.39
-1.81
-82.27%
Quince Therapeutics Corporate Events
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Quince Therapeutics Faces Nasdaq Listing Compliance Challenges
Negative
Sep 4, 2026
On August 31, 2026, Quince Therapeutics received a Nasdaq notice that, based on its June 30, 2026 Form 10-Q, the company reported negative stockholders’ equity of $35.3 million, falling short of the $10 million minimum required under Nasdaq ...
Executive/Board Changes
Quince Therapeutics Announces Planned Presidential Leadership Transition
Neutral
Aug 27, 2026
Quince Therapeutics, Inc. reported that on August 23, 2026, the company and its President, Charles Ryan, agreed that his last day of employment will be September 8, 2026, marking a planned leadership transition. In connection with his departure, R...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
Quince Plans Shareholder Vote on Major Stock Issuance
Neutral
Aug 17, 2026
Quince Therapeutics plans to convene a special shareholder meeting to seek approval for issuing a substantial number of new common shares upon conversion of its Series C Non-Voting Convertible Preferred Stock, as well as from related warrants and ...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingShareholder Meetings
Quince Therapeutics Announces Leadership Transition to Orphai Team
Neutral
Jul 31, 2026
On July 29, 2026, Quince Therapeutics announced that CEO and Chief Medical Officer Dirk Thye, who also serves on the board, and COO, Chief Business Officer and Chief Compliance Officer Brendan Hannah tendered conditional resignations, effective tw...
Regulatory Filings and ComplianceShareholder MeetingsStock Split
Quince Therapeutics Implements 1-for-20 Reverse Stock Split
Neutral
Jun 26, 2026
On June 11, 2026, stockholders of Quince Therapeutics approved a reverse stock split at a ratio range of 1-for-10 to 1-for-100, and the board later set the ratio at 1-for-20. The company filed a certificate of amendment in Delaware on June 26, 202...
Executive/Board ChangesShareholder MeetingsStock Split
Quince Therapeutics Stockholders Approve Reverse Split Authorization
Neutral
Jun 11, 2026
On June 11, 2026, Quince Therapeutics held its annual meeting of stockholders via live webcast, with approximately 38.37% of outstanding shares represented. Stockholders elected June Bray as a Class I director to serve until the 2029 annual meetin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.